ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EW / options
STE (71) ISRG (72) ZBH (68) SNN (58) ⌘ Pro Terminal →

Edwards Lifesciences Corporation (EW) Options Positioning, Max Pain & Unusual Sweeps

$93.26 +1.36% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $93.71

Edwards Lifesciences Corporation (EW) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (78% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $53.03B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EW Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Edwards Lifesciences Corporation (NYSE: EW) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $93.26 (+1.36% 1D, market cap $53.03B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, EW ranks #20 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EW compare to STE and ISRG in the Health Care sector?
▼

Within the Health Care sector (Industrial Specialties), EW carries a Roarable B+ (78/100 RQD), trailing P/E of 50.7x, gross margin of 78.0%, and ROIC of 12.5%. By comparison, STE (STERIS plc (Ireland)) holds a B- grade (71/100 RQD, P/E 28.9x, ROIC 10.1%, cap $22.14B) and ISRG (Intuitive Surgical Inc.) posts a B grade (72/100 RQD, P/E 54.5x, ROIC 15.0%, cap $149.75B). Among the 5-stock peer group, ZBH leads on earnings multiple (26.4x) while ISRG leads on capital efficiency (15.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EW?
▼

Per EW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001099800), Edwards Lifesciences Corporation generated $6.07B in revenue (+11.5% YoY), $1.07B in net income, and $1.33B in free cash flow against $13.70B in total assets and $598.3M in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 51x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $93.71 (+0.48%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 22% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510078
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B+
Cash (17)Whales (17)SEC (18)Macro (14)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+9% Base Target
$120 Bull$102 Base$76 Bear
📬 FREE EW RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EW)Realized 20D OHLCV Swing Band: ±5.5%
Deterministic 5-Pillar Attribution (78/100 Composite)
🔍 WHY EW SCORES 78/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (23% of score)

Altman Z-Score 12.36 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 22% FCF Margin ($1.33B FCF) & 78% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
70
Grade B$86.45+2.3% Next Q
Q2 (-2Q)
73
Grade B$88.40+3.8% Next Q
Q3 (-1Q)
75
Grade B+$91.78+1.6% Next Q
Current
78
Grade B+$93.26+7.9% Hist 90D α
Trajectory: B (70) → B+ (78)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EW Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 78/100 (B+) score, EW faces multiple-compression risk if 50.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 51x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 75.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($88.34) or 200D SMA ($85.57) invalidates the momentum regime and cuts Target Base ($101.65) toward Bear Floor ($76.47).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EW• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EW Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 78%NO 22%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±5.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (EW)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for EW.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating EW & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on EW
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.92%📐 HORIZONTAL RANGE
2026-11-03O $94.44H $94.44L $92.01C $93.26VOL 6.04M
RES: $95.42SUP: $82.89SMA50: $88.34SMA200: $85.57
$97.68$91.93$86.19$80.45$74.71RES $95.42SUP $82.89$93.262026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EW Butterfly Map → + Track EW →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
36.7%/yr Implied 5Y Growth

vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EW today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EW. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EW)

Health Care Rank #20 of 1016 ⚔️ STE vs EW Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EW vs. STE, ISRG, ZBH, SNN)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Edwards Lifesciences Corporation (EW) ranks #20 by composite RQD confidence (78/100, grade B+) and #37 by equity capitalization ($53.03B). Within this direct 5-issuer industry benchmark cohort, ZBH leads on earnings valuation at 26.4x trailing P/E, while ISRG leads on capital efficiency and profitability with 15.0% ROIC and 66.0% gross margin. EW currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EW ACTIVE
Edwards Lifesciences Corporation
B+ 78/100 50.7x 78.0% 12.5% +1.36% $53.03B Benchmark Subject
STE
STERIS plc (Ireland)
B- 71/100 28.9x 44.2% 10.1% +2.74% $22.14B /ste-vs-ew →
ISRG
Intuitive Surgical Inc.
B 72/100 54.5x 66.0% 15.0% +1.13% $149.75B /isrg-vs-ew →
ZBH
Zimmer Biomet Holdings Inc.
C+ 68/100 26.4x 69.7% 4.6% +2.99% $18.03B /zbh-vs-ew →
SNN
Smith & Nephew SNATS Inc.
D+ 58/100 32.8x — 9.9% +1.82% $12.44B /snn-vs-ew →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001099800

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Edwards Lifesciences Corporation (EW) reported GAAP revenue of $6.07B (+11.5% vs. FY2024 revenue of $5.44B , and +21.1% cumulative change since FY2023) , GAAP net income of $1.07B, operating cash flow of $1.60B, and free cash flow of $1.33B (+360.5% YoY). On the balance sheet, EW closed FY2025 with $13.70B in total assets against $598.3M in total debt (Altman Z-Score: 12.36, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.07B $1.07B $1.60B $1.33B $13.70B $598.3M
FY2024 (FY) 2024-12-31 $5.44B $4.17B $542.3M $289.9M $13.06B $597.7M
FY2023 (FY) 2023-12-31 $5.01B $1.40B $895.8M $670.4M $29.94B $7.01B

3. EW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Edwards Lifesciences Corporation (NYSE: EW) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $93.26 (+1.36% 1D, market cap $53.03B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, EW ranks #20 in composite RQD confidence.

How does EW compare to STE and ISRG in the Health Care sector?

Within the Health Care sector (Industrial Specialties), EW carries a Roarable B+ (78/100 RQD), trailing P/E of 50.7x, gross margin of 78.0%, and ROIC of 12.5%. By comparison, STE (STERIS plc (Ireland)) holds a B- grade (71/100 RQD, P/E 28.9x, ROIC 10.1%, cap $22.14B) and ISRG (Intuitive Surgical Inc.) posts a B grade (72/100 RQD, P/E 54.5x, ROIC 15.0%, cap $149.75B). Among the 5-stock peer group, ZBH leads on earnings multiple (26.4x) while ISRG leads on capital efficiency (15.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EW?

Per EW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001099800), Edwards Lifesciences Corporation generated $6.07B in revenue (+11.5% YoY), $1.07B in net income, and $1.33B in free cash flow against $13.70B in total assets and $598.3M in total debt. Key quantitative strengths: Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 51x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EW trading relative to its 50-day, 200-day, and 52-week technical levels?

EW last traded at $93.26 (+1.36% on volume of 12,172,848 shares), positioning the stock +5.57% above its 50-day simple moving average ($88.34) and +8.99% above its 200-day simple moving average ($85.57). Across its 52-week range of $74.66 to $96.29, EW sits at the 86.0% percentile with a 14-day RSI of 56.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.5% ($88.13 to $98.39).

Direct Sub-Reports: EW RQD Cockpit EW 12M Forecast EW Earnings & Move EW Dividends & DRIP EW Insiders & 13F EW Whale Options EW Profit Sankey EW News & Why
ROARABLE RATING BRIEF • RQD 78/100 (B+) ✓ SEC XBRL & RQD VERIFIED

EW — Edwards Lifesciences Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Edwards Lifesciences Corporation (EW) earns a live Roarable RQD composite score of 78/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $93.26 (+1.36% 1D, market capitalization $53.03B).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 12.5%, gross margin of 78.0%, operating margin of 20.8%, and free cash flow yield of 2.45%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (12/20): Incorporates a 1.08x equity beta, Altman Z-Score of 12.36, Piotroski F-Score of 8/9, and Debt/Equity of 0.06x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Edwards Lifesciences Corporation (EW) is a NYSE-listed issuer in the Health Care sector, classified under Industrial Specialties. Per the market data, the company reports a gross margin of 78% and an operating margin of 20.8%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Edwards Lifesciences Corporation (EW) reported $6.07B in annual revenue (up from $5.44B in FY2024, +11.5% YoY) and $1.07B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.01B revenue, $1.40B net income) through FY2025, EW scaled operating cash flow to $1.60B and free cash flow to $1.33B, backed by $13.70B in total assets against $598.3M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B+ • RQD 78/100): Strong cash generator (78% profit margin)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $74.66 – $96.29 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 51x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 50.7x trailing P/E and 35.1x EV/EBITDA against 20.8% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Industrial Specialties (Health Care), EW carries a macro regime beta of 1.08 and gross margin of 78.0%.

  • Key Question #1: Can EW sustain or expand its 20.8% operating margin and 12.5% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.07B and free cash flow of $1.33B, how will capital allocation balance growth reinvestment against $598.3M in total debt?
  • Key Question #3: How sensitive is EW's 47.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

EW Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Edwards Lifesciences Corporation (EW) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EW Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EW Bull vs. Bear Conversation Board — What's Your Call at $93.26?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EW 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EW:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $105.81 (+15.0%)
📌 Pinned Debate

Per the Roarable RQD rating, a 17/20 cash engine (ROIC 12.5%) and 18/20 forensic balance sheet (Altman Z 12.36, Debt/Equity 0.06) suppo

Per the Roarable RQD rating, a 17/20 cash engine (ROIC 12.5%) and 18/20 forensic balance sheet (Altman Z 12.36, Debt/Equity 0.06) support the rating's Buy label.. When you look under the hood at EW, Fundamental Cash Engine is 17/20 with 78.0% gross margins and 12.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (17/20) has been quietly accumulating below $96.29. My 12M target is $105.81.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 17/20 institutional whale-flow stock at $92.01 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $69.01 (-25.0%)
Spot @ $92.01

Per the market data, a 2.45% FCF yield and 50.7x trailing P/E leave little valuation cushion against a 1.08 beta.

Careful chasing EW at $92.01. Per the market data, a 2.45% FCF yield and 50.7x trailing P/E leave little valuation cushion against a 1.08 beta.. Gross margin is 78.0%, but operating margin is 20.8%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $69.01 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%